Carbonyl reduction pathways in drug metabolism

Drug Metabolism Reviews

Volumn 46, Issue 1, 2014, Pages 96-123

  Malátková, Petra ^a   Wsól, Vladimír ^a  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

Author keywords

Aldo keto reductase; Carbonyl reductase; Carbonyl reducing enzymes; Hydroxysteroid dehydrogenase; Reductive drug metabolism; Short chain dehydrogenase reductase

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; 17 METHYLNALTREXONE; AMFEBUTAMONE; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; BENFLURON; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOCEPREVIR; CARBONYL DERIVATIVE; CARBONYL REDUCTASE; EPERISONE; FENOFIBRATE; FENOFIBRIC ACID; GLUCOCORTICOID; HYDROXYSTEROID DEHYDROGENASE; METYRAPONE; NABUMETONE; NAFTAZONE; NORETYNODREL; OXCARBAZEPINE; PENTOXIFYLLINE; QUINONE DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; RETINOL DEHYDROGENASE; TIBOLONE; TOLPERISONE; WARFARIN; WORTMANNIN; XENOBIOTIC AGENT;

AMINO ACID SEQUENCE; ANTICOAGULATION; AREA UNDER THE CURVE; CARBONYL REDUCTION; CELLULAR DISTRIBUTION; CUSHING SYNDROME; CYTOSOLIC FRACTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; DRUG TRANSFORMATION; ENDOPLASMIC RETICULUM; ENZYME ACTIVITY; GOLGI COMPLEX; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; MAXIMUM PLASMA CONCENTRATION; METABOLITE; REDUCTION; REVIEW; STEREOCHEMISTRY; STEREOSPECIFICITY; XENOBIOTIC METABOLISM;

ALCOHOL OXIDOREDUCTASES; ANIMALS; BIOTRANSFORMATION; HUMANS; METABOLIC DETOXICATION, DRUG; OXIDATION-REDUCTION;

EID: 84893213752     PISSN: 03602532     EISSN: 10979883     Source Type: Journal    
DOI: 10.3109/03602532.2013.853078     Document Type: Review

References (208)

1. Adeniji AO, Twenter BM, Byrns MC, et al. (2011). Discovery of substituted 3-(phenylamino)benzoic acids as potent and selective inhibitors of type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3). Bioorg Med Chem Lett 21:1464-1468.
2. Arampatzis S, Kadereit B, Schuster D, et al. (2005). Comparative enzymology of 11beta-hydroxysteroid dehydrogenase type 1 from six species. J Mol Endocrinol 35:89-101.
3. Atalla A, Breyer-Pfaff U, Maser E. (2000). Purification and characterization of oxidoreductases-catalyzing carbonyl reduction of the tobacco-specific nitrosamine 4-methylnitrosamino-1-(3-pyridyl)-1- butanone (NNK) in human liver cytosol. Xenobiotica 30:755-769.
4. Atanasov AG, Nashev LG, Schweizer RA, et al. (2004). Hexose-6- phosphate dehydrogenase determines the reaction direction of 11betahydroxysteroid dehydrogenase type 1 as an oxoreductase. FEBS Lett 571:129-133.
5. Azuma Y, Nishinaka T, Ushijima S, et al. (2004). Characterization of htAKR, a novel gene product in the aldo-keto reductase family specifically expressed in human testis. Mol Hum Reprod 10: 527-533.
6. Bae JW, Park YS, Sohn UD, et al. (2006). HPLC determination of tolperisone in human plasma. Arch Pharm Res 29:339-342.
7. Bahr V, Oelkers W, Pfeiffer AF, Diederich S. (2007). Metabolism of synthetic steroids by the human placenta. Placenta 28:588-589.
8. Banfield C, Rowland M. (1984). Stereospecific fluorescence highperformance liquid chromatographic analysis of warfarin and its metabolites in plasma and urine. J Pharm Sci 73:1392-6.
9. Bannenberg G, Martin HJ, Belai I, Maser E. (2003). 11beta- Hydroxysteroid dehydrogenase type 1: Tissue-specific expression and reductive metabolism of some anti-insect agent azole analogues of metyrapone. Chem Biol Interact 143-144:449-457.
10. Barf T, Vallgarda J, Emond R, et al. (2002). Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs. Discovery of potent and selective inhibitors of the 11beta-hydroxysteroid dehydrogenase type 1. J Med Chem 45:3813-3815.
11. Barnes PJ. (2010). Mechanisms and resistance in glucocorticoid control of inflammation. J Steroid Biochem Mol Biol 120:76-85.
12. Barski OA, Tipparaju SM, Bhatnagar A. (2008). The aldo-keto reductase superfamily and its role in drug metabolism and detoxification. Drug Metab Rev 40:553-624.
13. Bialer M. (2006). New antiepileptic drugs that are second generation to existing antiepileptic drugs. Expert Opin Investig Drugs 15:637-647.
14. Bodor N, Buchwald P. (2005). Ophthalmic drug design based on the metabolic activity of the eye: Soft drugs and chemical delivery systems. AAPS J 7:E820-E833.
15. Breyer-Pfaff U, Nill K. (2004). Carbonyl reduction of naltrexone and dolasetron by oxidoreductases isolated from human liver cytosol. J Pharm Pharmacol 56:1601-1606.
16. Bryce TA, Chamberlain J, Hillbeck D, Macdonald CM. (1989). Metabolism and pharmacokinetics of 14C-pentoxifylline in healthy volunteers. Arzneimittelforschung 39:512-517.
17. Butler J, Gray CH. (1970). The metabolism of betamethasone. J Endocrinol 46:379-390.
18. Byrns MC, Steckelbroeck S, Penning TM. (2008). An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3alpha-HSD, type 5 17beta-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies. Biochem Pharmacol 75:484-493.
19. Caldwell J. (1989). The biochemical pharmacology of fenofibrate. Cardiology 76:33-41 [Abstract].
20. Chan E, McLachlan AJ, Pegg M, et al. (1994). Disposition of warfarin enantiomers and metabolites in patients during multiple dosing with rac-warfarin. Br J Clin Pharmacol 37:563-569.
21. Chan KK, Lewis RJ, Trager WF. (1972). Absolute configurations of the four warfarin alcohols. J Med Chem 15:1265-1270.
22. Chandrasekaran A, Tong Z, Li H, et al. (2010). Metabolism of intravenous methylnaltrexone in mice, rats, dogs, and humans. Drug Metab Dispos 38:606-616.
23. Chapman MJ. (1987). Pharmacology of fenofibrate. Am J Med 83:21- 25.
24. Chen Q, Zhang T, Wang JF, Wei DQ. (2011). Advances in human cytochrome p450 and personalized medicine. Curr Drug Metab 12: 436-444.
25. Chen S, Wu K, Zhang D, et al. (1999). Molecular characterization of binding of substrates and inhibitors to DT-diaphorase: Combined approach involving site-directed mutagenesis, inhibitor-binding analysis, and computer modeling. Mol Pharmacol 56:272-278.
26. Chen Y, Liu HF, Liu L, et al. (2010). The in vitro metabolism of bupropion revisited: Concentration dependent involvement of cytochrome P450 2C19. Xenobiotica 40:536-546.
27. Chetyrkin SV, Belyaeva OV, Gough WH, Kedishvili NY. (2001). Characterization of a novel type of human microsomal 3alpha -hydroxysteroid dehydrogenase: Unique tissue distribution and catalytic properties. J Biol Chem 276:22278-22286.
28. Chiarotto JA, Wainer IW. (1995). Determination of metyrapone and the enantiomers of its chiral metabolite metyrapol in human plasma and urine using coupled achiral-chiral liquid chromatography. J Chromatogr B Biomed Appl 665:147-154.
29. Choonara IA, Haynes BP, Cholerton S, et al. (1986). Enantiomers of warfarin and vitamin K1 metabolism. Br J Clin Pharmacol 22:729- 732.
30. Chu X, Cai X, Cui D, et al. (2013). In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters. Drug Metab Dispos 41:668-681.
31. Coles R, Kharasch ED. (2007). Stereoselective analysis of bupropion and hydroxybupropion in human plasma and urine by LC/MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 857:67-75.
32. Cook CE, Twine ME, Tallent CR, et al. (1972). Norethynodrel metabolites in human plasma and urine. J Pharmacol Exp Ther 183: 197-205 [Abstract].
33. Cornu-Chagnon MC, Dupont H, Edgar A. (1995). Fenofibrate: Metabolism and species differences for peroxisome proliferation in cultured hepatocytes. Fundam Appl Toxicol 26:63-74.
34. Czock D, Keller F, Rasche FM, Haussler U. (2005). Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet 44:61-98.
35. Dalmadi B, Leibinger J, Szeberenyi S, et al. (2003). Identification of metabolic pathways involved in the biotransformation of tolperisone by human microsomal enzymes. Drug Metab Dispos 31:631-636.
36. Denison MS, Nagy SR. (2003). Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Annu Rev Pharmacol Toxicol 43:309-334.
37. Denooz R, Mercerolle M, Lachatre G, Charlier C. (2010). Ultraperformance liquid chromatography- tandem mass spectrometry method for the determination of bupropion and its main metabolites in human whole blood. J Anal Toxicol 34:280-286.
38. Diederich S, Eigendorff E, Burkhardt P, et al. (2002). 11betahydroxysteroid dehydrogenase types 1 and 2: An important pharmacokinetic determinant for the activity of synthetic mineralo- and glucocorticoids. J Clin Endocrinol Metab 87:5695-5701.
39. Durackova Z. (2010). Some current insights into oxidative stress. Physiol Res 59:459-469.
40. Dwoskin LP, Rauhut AS, King-Pospisil KA, Bardo MT. (2006). Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent. CNS Drug Rev 12:178-207.
41. Endo S, Matsunaga T, Soda M, et al. (2010). Selective inhibition of the tumor marker AKR1B10 by antiinflammatory N-phenylanthranilic acids and glycyrrhetic acid. Biol Pharm Bull 33:886-890.
42. Escande A, Servant N, Rabenoelina F, et al. (2009). Regulation of activities of steroid hormone receptors by tibolone and its primary metabolites. J Steroid Biochem Mol Biol 116:8-14.
43. Escher G, Frey FJ, Frey BM. (1994). 11 beta-Hydroxysteroid dehydrogenase accounts for low prednisolone/prednisone ratios in the kidney. Endocrinology 135:101-106.
44. Estabrook RW. (2003). A passion for P450s (rememberances of the early history of research on cytochrome P450). Drug Metab Dispos 31: 1461-1473.
45. Faucette SR, Hawke RL, LeCluyse EL, et al. (2000). Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos 28: 1222-1230.
46. Faucette SR, Hawke RL, Shord SS, et al. (2001). Evaluation of the contribution of cytochrome P450 3A4 to human liver microsomal bupropion hydroxylation. Drug Metab Dispos 29:1123-1129.
47. Feitosa MF, An P, Ordovas JM, et al. (2011). Association of gene variants with lipid levels in response to fenofibrate is influenced by metabolic syndrome status. Atherosclerosis 215:435-439.
48. Finlay MR, Griffin RJ. (2012). Modulation of DNA repair by pharmacological inhibitors of the PIKK protein kinase family. Bioorg Med Chem Lett 22:5352-5359.
49. Flesch G. (2004). Overview of the clinical pharmacokinetics of oxcarbazepine. Clin Drug Investig 24:185-203.
50. Flesch G, Francotte E, Hell F, Degen PH. (1992). Determination of the R-(-) and S-(+) enantiomers of the monohydroxylated metabolite of oxcarbazepine in human plasma by enantioselective highperformance liquid chromatography. J Chromatogr 581:147-151 [Abstract].
51. Fortuna A, Alves G, Falcao A, Soares-da-Silva P. (2010). Binding of licarbazepine enantiomers to mouse and human plasma proteins. Biopharm Drug Dispos 31:362-366.
52. Friel PN, Logan BK, Fligner CL. (1993). Three fatal drug overdoses involving bupropion. J Anal Toxicol 17:436-438.
53. Frishman WH, Kowalski M, Nagnur S, et al. (2001). Cardiovascular considerations in using topical, oral, and intravenous drugs for the treatment of glaucoma and ocular hypertension: Focus on betaadrenergic blockade. Heart Dis 3:386-397.
54. Garg V, Jusko WJ. (1991). Simultaneous analysis of prednisone, prednisolone and their major hydroxylated metabolites in urine by high-performance liquid chromatography. J Chromatogr 567: 39-47.
55. Gebauer M. (2007). Synthesis and structure-activity relationships of novel warfarin derivatives. Bioorg Med Chem 15:2414-2420.
56. Ghosal A, Yuan Y, Tong W, et al. (2011). Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor. Drug Metab Dispos 39:510-521.
57. GlaxoSmithKline (2013). Wellbutrin (bupropion hydrochloride). Research Triangle Park: GlaxoSmithKline.
58. Gobec S, Brozic P, Rizner TL. (2005). Nonsteroidal anti-inflammatory drugs and their analogues as inhibitors of aldo-keto reductase AKR1C3: New lead compounds for the development of anticancer agents. Bioorg Med Chem Lett 15:5170-5175.
59. Gough WH, VanOoteghem S, Sint T, Kedishvili NY. (1998). cDNA cloning and characterization of a new human microsomal NAD+dependent dehydrogenase that oxidizes all-trans-retinol and 3alphahydroxysteroids. J Biol Chem 273:19778-19785.
60. Gronau S, Koenig GD, Jerg M, Riechelmann H. (2002). 11Beta-hydroxysteroid dehydrogenase 1 expression in squamous cell carcinomas of the head and neck. Clin Otolaryngol Allied Sci 27: 453-457.
61. Haddock RE, Jeffery DJ, Lloyd JA, Thawley AR. (1984). Metabolism of nabumetone (BRL 14777) by various species including man. Xenobiotica 14:327-337.
62. Hainzl D, Parada A, Soares-da-Silva P. (2001). Metabolism of two new antiepileptic drugs and their principal metabolites S(+)- and R(-)- 10,11-dihydro-10-hydroxy carbamazepine. Epilepsy Res 44:197-206.
63. Hedner T, Samulesson O, Wahrborg P, et al. (2004). Nabumetone: Therapeutic use and safety profile in the management of osteoarthritis and rheumatoid arthritis. Drugs 64:2315-2343.
64. Herber R, Hercelin B, Van CJ, et al. (1995). Reduction and glucuronidation of naftazone by human and rat liver microsomes. Drug Metab Dispos 23:1305-1314.
65. Hermans JJ, Thijssen HH. (1989). The in vitro ketone reduction of warfarin and analogues. Substrate stereoselectivity, product stereoselectivity and species differences. Biochem Pharmacol 38: 3365-3370.
66. Hermans JJ, Thijssen HH. (1992). Stereoselective acetonyl side chain reduction of warfarin and analogs. Partial characterization of two cytosolic carbonyl reductases. Drug Metab Dispos 20:268-274.
67. Hermans JJ, Thijssen HH. (1993). Properties and stereoselectivity of carbonyl reductases involved in the ketone reduction of warfarin and analogues. Adv Exp Med Biol 328:351-360.
68. Hesse LM, He P, Krishnaswamy S, et al. (2004). Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. Pharmacogenetics 14:225-238.
69. Hesse LM, Venkatakrishnan K, Court MH, et al. (2000). CYP2B6 mediates the in vitro hydroxylation of bupropion: Potential drug interactions with other antidepressants. Drug Metab Dispos 28: 1176-1183.
70. Hewick DS, McEwen J. (1973). Plasma half-lives, plasma metabolites and anticoagulant efficacies of the enantiomers of warfarin in man. J Pharm Pharmacol 25:458-465.
71. Hewick DS, Moreland TA. (1975). An NADPH dependent warfarin reductase in human and rat liver and kidney soluble fraction. Br J Pharmacol 53:441P.
72. Higaki Y, Usami N, Shintani S, et al. (2003). Selective and potent inhibitors of human 20alpha-hydroxysteroid dehydrogenase (AKR1C1) that metabolizes neurosteroids derived from progesterone. Chem Biol Interact 143-144:503-513.
73. Hoffmann F, Maser E. (2007). Carbonyl reductases and pluripotent hydroxysteroid dehydrogenases of the short-chain dehydrogenase/reductase superfamily. Drug Metab Rev 39:87-144.
74. Holbrook AM, Pereira JA, Labiris R, et al. (2005). Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 165: 1095-1106.
75. Holleran JL, Egorin MJ, Zuhowski EG, et al. (2003). Use of highperformance liquid chromatography to characterize the rapid decomposition of wortmannin in tissue culture media. Anal Biochem 323: 19-25.
76. Hsyu PH, Singh A, Giargiari TD, et al. (1997). Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers. J Clin Pharmacol 37:737-743.
77. Huang SP, Palla S, Ruzycki P, et al. (2010). Aldo-keto reductases in the eye. J Ophthalmol 2010:521204.
78. Huuskonen P, Storvik M, Reinisalo M, et al. (2008). Microarray analysis of the global alterations in the gene expression in the placentas from cigarette-smoking mothers. Clin Pharmacol Ther 83: 542-550.
79. Igaz P, Tombol Z, Szabo PM, et al. (2008). Steroid biosynthesis inhibitors in the therapy of hypercortisolism: Theory and practice. Curr Med Chem 15:2734-2747.
80. Jefferson JW, Pradko JF, Muir KT. (2005). Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations. Clin Ther 27:1685-1695.
81. Jin Y. (2011). Activities of aldo-keto reductase 1 enzymes on two inhaled corticosteroids: Implications for the pharmacological effects of inhaled corticosteroids. Chem Biol Interact 191:234-238.
82. Jin Y, Duan L, Chen M, et al. (2012). Metabolism of the synthetic progestogen norethynodrel by human ketosteroid reductases of the aldo-keto reductase superfamily. J Steroid Biochem Mol Biol 129: 139-144.
83. Jin Y, Duan L, Lee SH, et al. (2009). Human cytosolic hydroxysteroid dehydrogenases of the aldo-ketoreductase superfamily catalyze reduction of conjugated steroids: Implications for phase I and phase II steroid hormone metabolism. J Biol Chem 284:10013-10022.
84. Jin Y, Penning TM. (2007). Aldo-keto reductases and bioactivation/ detoxication. Annu Rev Pharmacol Toxicol 47:263-292.
85. Johannessen LC, Patsalos PN. (2010). Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Rev Neurother 10:119-140.
86. Jonas DE, McLeod HL. (2009). Genetic and clinical factors relating to warfarin dosing. Trends Pharmacol Sci 30:375-386.
87. Jones DR, Boysen G, Miller GP. (2011). Novel multi-mode ultra performance liquid chromatography-tandem mass spectrometry assay for profiling enantiomeric hydroxywarfarins and warfarin in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 879: 1056-1062.
88. Jones DR, Miller GP. (2011). Assays and applications in warfarin metabolism: What we know, how we know it and what we need to know. Expert Opin Drug Metab Toxicol 7:857-874.
89. Keenan CR, Salem S, Fietz ER, et al. (2012). Glucocorticoid-resistant asthma and novel anti-inflammatory drugs. Drug Discov Today 17: 1031-1038.
90. Kharasch ED, Mitchell D, Coles R. (2008). Stereoselective bupropion hydroxylation as an in vivo phenotypic probe for cytochrome P4502B6 (CYP2B6) activity. J Clin Pharmacol 48:464-474.
91. Kim DW, Gu N, Jang IJ, et al. (2012). Efficacy, tolerability, and pharmacokinetics of oxcarbazepine oral loading in patients with epilepsy. Epilepsia 53:e9-12.
92. Kim SH, Ramu R, Kwon SW, et al. (2010). Discovery of cyclicsulfonamide derivatives as 11 beta-hydroxysteroid dehydrogenase 1 inhibitors. Bioorg Med Chem Lett 20:1065-1069.
93. King AC, Volpicelli JR, Gunduz M, et al. (1997). Naltrexone biotransformation and incidence of subjective side effects: A preliminary study. Alcohol Clin Exp Res 21:906-909.
94. Kornel L, Saito Z, Yuan LC. (1980). Corticosteroids in human blood- VII. Isolation, characterization and quantitation of glucuronideconjugated metabolites of cortisol in human plasma. J Steroid Biochem 13:751-771.
95. Kucera R, Nobilis M, Skalova L, et al. (2005). Use of chiral liquid chromatography for the evaluation of stereospecificity in the carbonyl reduction of potential benzo[c]fluorene antineoplastics benfluron and dimefluron in various species. J Pharm Biomed Anal 37:1049-1057.
96. Lakhman SS, Chen X, Gonzalez-Covarrubias V, et al. (2007). Functional characterization of the promoter of human carbonyl reductase 1 (CBR1). Role of XRE elements in mediating the induction of CBR1 by ligands of the aryl hydrocarbon receptor. Mol Pharmacol 72: 734-743.
97. Lavery GG, Walker EA, Draper N, et al. (2006). Hexose-6-phosphate dehydrogenase knock-out mice lack 11 beta-hydroxysteroid dehydrogenase type 1-mediated glucocorticoid generation. J Biol Chem 281: 6546-6551.
98. Lee SH, Slattery JT. (1997). Cytochrome P450 isozymes involved in lisofylline metabolism to pentoxifylline in human liver microsomes. Drug Metab Dispos 25:1354-1358.
99. Lee VH, Chien DS, Sasaki H. (1988). Ocular ketone reductase distribution and its role in the metabolism of ocularly applied levobunolol in the pigmented rabbit. J Pharmacol Exp Ther 246: 871-878.
100. Leinweber FJ. (1991). Drug disposition in the mammalian eye and brain: A comparison of mechanisms. Drug Metab Rev 23:133-246.
101. Leinweber FJ, Szpiech JM, Di Carlo FJ. (1978). l-bunolol metabolites in human urine. Pharmacology 16:70-77.
102. Lewis RJ, Trager WF. (1970). Warfarin metabolism in man: Identification of metabolites in urine. J Clin Invest 49:907-913.
103. Lewis RJ, Trager WF. (1971). The metabolic fate of warfarin: Studies on the metabolites in plasma. Ann N Y Acad Sci 179:205-212.
104. Lewis RJ, Trager WF, Chan KK, et al. (1974). Warfarin. Stereochemical aspects of its metabolism and the interaction with phenylbutazone. J Clin Invest 53:1607-1617.
105. Li F, Cooper SF, Cote M, Ayotte C. (1994). Determination of the enantiomers of bunolol in human urine by high-performance liquid chromatography on a chiral AGP stationary phase and identification of their metabolites by gas chromatography-mass spectrometry. J Chromatogr B Biomed Appl 660:327-339.
106. Li KX, Obeyesekere VR, Krozowski ZS, Ferrari P. (1997). Oxoreductase and dehydrogenase activities of the human and rat 11beta-hydroxysteroid dehydrogenase type 2 enzyme. Endocrinology 138: 2948-2952.
107. Li TK, Theorell H. (1969). Human liver alcohol dehydrogenase: Inhibition by pyrazole and pyrazole analogs. Acta Chem Scand 23: 892-902.
108. Lillibridge JA, Kalhorn TF, Slattery JT. (1996). Metabolism of lisofylline and pentoxifylline in human liver microsomes and cytosol. Drug Metab Dispos 24:1174-1179.
109. Liu A, Patterson AD, Yang Z, et al. (2009). Fenofibrate metabolism in the cynomolgus monkey using ultraperformance liquid chromatography- quadrupole time-of-flight mass spectrometry-based metabolomics. Drug Metab Dispos 37:1157-1163.
110. Locatelli I, Kmetec V, Mrhar A, Grabnar I. (2005). Determination of warfarin enantiomers and hydroxylated metabolites in human blood plasma by liquid chromatography with achiral and chiral separation. J Chromatogr B Analyt Technol Biomed Life Sci 818: 191-198.
111. Magnusson M, Gunnarsson M, Berntorp E, et al. (2008). Effects of pentoxifylline and its metabolites on platelet aggregation in whole blood from healthy humans. Eur J Pharmacol 581:290-295.
112. Maira SM, Stauffer F, Schnell C, Garcia-Echeverria C. (2009). PI3K inhibitors for cancer treatment: Where do we stand? Biochem Soc Trans. 37:265-272.
113. Malatkova P, Maser E, Wsol V. (2010). Human carbonyl reductases. Curr Drug Metab 11:639-658.
114. Manns MP, Markova AA, Calle SB, Cornberg M. (2012). Phase III results of Boceprevir in treatment naive patients with chronic hepatitis C genotype 1. Liver Int 32:27-31.
115. Martin HJ, Breyer-Pfaff U, Wsol V, et al. (2006). Purification and characterization of akr1b10 from human liver: Role in carbonyl reduction of xenobiotics. Drug Metab Dispos 34:464-470.
116. Marwick JA, Chung KF. (2010). Glucocorticoid insensitivity as a future target of therapy for chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 5:297-309.
117. Maser E, Friebertshauser J, Volker B. (2003). Purification, characterization and NNK carbonyl reductase activities of 11beta-hydroxysteroid dehydrogenase type 1 from human liver: Enzyme cooperativity and significance in the detoxification of a tobacco-derived carcinogen. Chem Biol Interact 143-144:435-448.
118. Maser E, Gebel T, Netter KJ. (1991). Carbonyl reduction of metyrapone in human liver. Biochem Pharmacol 42:S93-S98.
119. Maser E, Oppermann UC. (1997). Role of type-1 11beta-hydroxysteroid dehydrogenase in detoxification processes. Eur J Biochem 249: 365-369.
120. Matabosch X, Pozo OJ, Perez-Mana C, et al. (2012). Identification of budesonide metabolites in human urine after oral administration. Anal Bioanal Chem 404:325-340.
121. Matsumoto K, Nemoto E, Hasegawa T, et al. (2011). In vitro characterization of the cytochrome P450 isoforms involved in the metabolism of 6-methoxy-2-napthylacetic acid, an active metabolite of the prodrug nabumetone. Biol Pharm Bull 34:734-739.
122. Matsunaga T, Shintani S, Hara A. (2006). Multiplicity of mammalian reductases for xenobiotic carbonyl compounds. Drug Metab Pharmacokinet 21:1-18.
123. Mazur CS, Kenneke JF, Goldsmith MR, Brown C. (2009). Contrasting influence of NADPH and a NADPH-regenerating system on the metabolism of carbonyl-containing compounds in hepatic microsomes. Drug Metab Dispos 37:1801-1805.
124. McMahon FG, Vargas R, Ryan JR, Fitts DA. (1987). Nabumetone kinetics in the young and elderly. Am J Med 83:92-95.
125. Mercerolle M, Denooz R, Lachatre G, Charlier C. (2008). A fatal case of bupropion (Zyban) overdose. J Anal Toxicol 32:192-196.
126. Meru AV, Mittra S, Thyagarajan B, Chugh A. (2006). Intermittent claudication: An overview. Atherosclerosis 187:221-237.
127. Meyer A, Vuorinen A, Zielinska AE, et al. (2013). Formation of threohydrobupropion from bupropion is dependent on 11betahydroxysteroid dehydrogenase 1. Drug Metab Dispos 41: 1671-1678.
128. Miller DB, Spence JD. (1998). Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet 34:155-162.
129. Miller GP, Jones DR, Sullivan SZ, et al. (2009). Assessing cytochrome P450 and UDP-glucuronosyltransferase contributions to warfarin metabolism in humans. Chem Res Toxicol 22:1239-1245.
130. Molnari JC, Myers AL. (2012). Carbonyl reduction of bupropion in human liver. Xenobiotica 42:550-561.
131. Mordente A, Meucci E, Silvestrini A, et al. (2009). New developments in anthracycline-induced cardiotoxicity. Curr Med Chem 16: 1656-1672.
132. Moreland TA, Hewick DS. (1975). Studies on a ketone reductase in human and rat liver and kidney soluble fraction using warfarin as a substrate. Biochem Pharmacol 24:1953-1957.
133. Myllynen P, Pienimaki P, Jouppila P, Vahakangas K. (2001). Transplacental passage of oxcarbazepine and its metabolites in vivo. Epilepsia 42:1482-1485.
134. Myllynen P, Pienimaki P, Raunio H, Vahakangas K. (1998). Microsomal metabolism of carbamazepine and oxcarbazepine in liver and placenta. Hum Exp Toxicol 17:668-676.
135. Nagamine S, Horisaka E, Fukuyama Y, et al. (1997). Stereoselective reductive metabolism of metyrapone and inhibitory activity of metyrapone metabolites, metyrapol enantiomers, on steroid 11 betahydroxylase in the rat. Biol Pharm Bull 20:188-192.
136. Najib J. (2002). Fenofibrate in the treatment of dyslipidemia: A review of the data as they relate to the new suprabioavailable tablet formulation. Clin Ther 24:2022-2050.
137. Nicklasson M, Bjorkman S, Roth B, et al. (2002). Stereoselective metabolism of pentoxifylline in vitro and in vivo in humans. Chirality 14:643-652.
138. Odermatt A, Kratschmar DV. (2012). Tissue-specific modulation of mineralocorticoid receptor function by 11beta-hydroxysteroid dehydrogenases: An overview. Mol Cell Endocrinol 350:168-186.
139. Odermatt A, Nashev LG. (2010). The glucocorticoid-activating enzyme 11beta-hydroxysteroid dehydrogenase type 1 has broad substrate specificity: Physiological and toxicological considerations. J Steroid Biochem Mol Biol 119:1-13.
140. Oesterheld JR, Cozza K, Sandson NB. (2008). Oral contraceptives. Psychosomatics 49:168-175.
141. Ohara H, Miyabe Y, Deyashiki Y, et al. (1995). Reduction of drug ketones by dihydrodiol dehydrogenases, carbonyl reductase and aldehyde reductase of human liver. Biochem Pharmacol 50: 221-227.
142. Oppermann U. (2007). Carbonyl reductases: The complex relationships of mammalian carbonyl- and quinone-reducing enzymes and their role in physiology. Annu Rev Pharmacol Toxicol 47:293-322.
143. Oppermann UC, Maser E. (2000). Molecular and structural aspects of xenobiotic carbonyl metabolizing enzymes. Role of reductases and dehydrogenases in xenobiotic phase I reactions. Toxicology 144: 71-81.
144. Patel P, Hardy R, Sumathi V, et al. (2012). Expression of 11betahydroxysteroid dehydrogenase enzymes in human osteosarcoma: Potential role in pathogenesis and as targets for treatments. Endocr Relat Cancer 19:589-598.
145. Patsalos PN, Berry DJ. (2012). Pharmacotherapy of the third-generation AEDs: lacosamide, retigabine and eslicarbazepine acetate. Expert Opin Pharmacother 13:699-715.
146. Paz MM, Zhang X, Lu J, Holmgren A. (2012). A new mechanism of action for the anticancer drug mitomycin C: Mechanismbased inhibition of thioredoxin reductase. Chem Res Toxicol 25: 1502-1511.
147. Penning TM, Burczynski ME, Jez JM, et al. (2000). Human 3alphahydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: Functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. Biochem J 351:67-77.
148. Penning TM, Jin Y, Heredia VV, Lewis M. (2003). Structure-function relationships in 3alpha-hydroxysteroid dehydrogenases: A comparison of the rat and human isoforms. J Steroid Biochem Mol Biol 85: 247-255.
149. Penning TM, Jin Y, Steckelbroeck S, et al. (2004). Structure-function of human 3 alpha-hydroxysteroid dehydrogenases: Genes and proteins. Mol Cell Endocrinol 215:63-72.
150. Persson B, Kallberg, Y. (2012). Classification and nomenclature of the superfamily of short-chain dehydrogenases/reductases (SDRs). Chem Biol Interact 202:111-115.
151. Pienimaki P, Lampela E, Hakkola J, et al. (1997). Pharmacokinetics of oxcarbazepine and carbamazepine in human placenta. Epilepsia 38: 309-316.
152. Pilka ES, Niesen FH, Lee WH, et al. (2009). Structural basis for substrate specificity in human monomeric carbonyl reductases. PLoS One 4:e7113.
153. Pirolli D, Giardina B, Mordente A, et al. (2012). Understanding the binding of daunorubicin and doxorubicin to NADPH-dependent cytosolic reductases by computational methods. Eur J Med Chem 56:145-154.
154. Porte S, Moeini A, Reche I, et al. (2011). Kinetic and structural evidence of the alkenal/one reductase specificity of human zeta-crystallin. Cell Mol Life Sci 68:1065-1077.
155. Pozo OJ, Marcos J, Matabosch X, et al. (2012). Using complementary mass spectrometric approaches for the determination of methylprednisolone metabolites in human urine. Rapid Commun Mass Spectrom 26:541-553.
156. Prokai L, Wu WM, Somogyi G, Bodor N. (1995). Ocular delivery of the beta-adrenergic antagonist alprenolol by sequential bioactivation of its methoxime analogue. J Med Chem 38:2018-2020.
157. Prueksaritanont T, Tang C, Qiu Y, et al. (2002). Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos 30: 1280-1287.
158. Quasthoff S, Mockel C, Zieglgansberger W, Schreibmayer W. (2008). Tolperisone: A typical representative of a class of centrally acting muscle relaxants with less sedative side effects. CNS Neurosci Ther 14:107-119.
159. Robertson S. (2011). Clinical pharmacology and biopharmaceutics review, application number 202258Orig1s000. Center for Drug Evaluation and Research. Food and Drug Administration. Reference ID: 2876973.
160. Rosemond MJ, Walsh JS. (2004). Human carbonyl reduction pathways and a strategy for their study in vitro. Drug Metab Rev 36: 335-361.
161. Saurav A, Kaushik M, Mohiuddin SM. (2012). Fenofibric acid for hyperlipidemia. Expert Opin Pharmacother 13:717-722.
162. Schmidt D, Elger CE. (2004). What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs? Epilepsy Behav 5:627-635.
163. Schutz H, Feldmann KF, Faigle JW, et al. (1986). The metabolism of 14C-oxcarbazepine in man. Xenobiotica 16:769-778.
164. Schweizer RA, Atanasov AG, Frey BM, Odermatt A. (2003). A rapid screening assay for inhibitors of 11beta-hydroxysteroid dehydrogenases (11beta-HSD): Flavanone selectively inhibits 11beta-HSD1 reductase activity. Mol Cell Endocrinol 212:41-49.
165. Shirasaki Y. (2008). Molecular design for enhancement of ocular penetration. J Pharm Sci 97:2462-2496.
166. Siegel D, Ross D. (2000). Immunodetection of NAD(P)H: Quinone oxidoreductase 1 (NQO1) in human tissues. Free Radic Biol Med 29: 246-253.
167. Siegel D, Yan C, Ross D. (2012). NAD(P)H: Quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones. Biochem Pharmacol 83:1033-1040.
168. Skalova L, Nobilis M, Szotakova B, et al. (2002). Carbonyl reduction of the potential cytostatic drugs benfluron and 3,9-dimethoxybenfluron in human in vitro. Biochem Pharmacol 64:297-305.
169. Skarka A, Skarydova L, Stambergova H, Wsol V. (2011). Anthracyclines and their metabolism in human liver microsomes and the participation of the new microsomal carbonyl reductase. Chem Biol Interact 191: 66-74.
170. Skarydova L, Nobilis M, Wsol V. (2013). Role of carbonyl reducing enzymes in the phase I biotransformation of the nonsteroidal anti-inflammatory drug nabumetone in vitro. Xenobiotica 43:346-354.
171. Skarydova L, Skarka A, Solich P, Wsol V. (2010). Enzyme stereospecificity as a powerful tool in searching for new enzymes. Curr Drug Metab 11:547-559.
172. Skarydova L, Wsol V. (2012). Human microsomal carbonyl reducing enzymes in the metabolism of xenobiotics: Well-known and promising members of the SDR superfamily. Drug Metab Rev 44: 173-191.
173. Spence JD. (1998). Metabolism of fibric acid derivatives. Clin Pharmacokinet 34:419-420.
174. Steckelbroeck S, Jin Y, Oyesanmi B, et al. (2004). Tibolone is metabolized by the 3alpha/3beta-hydroxysteroid dehydrogenase activities of the four human isozymes of the aldo-keto reductase 1C subfamily: Inversion of stereospecificity with a delta5(10)-3- ketosteroid. Mol Pharmacol 66:1702-1711.
175. Steckelbroeck S, Oyesanmi B, Jin Y, et al. (2006). Tibolone metabolism in human liver is catalyzed by 3alpha/3beta-hydroxysteroid dehydrogenase activities of the four isoforms of the aldo-keto reductase (AKR)1C subfamily. J Pharmacol Exp Ther 316:1300-1309.
176. Stewart JJ, Berkel HJ, Parish RC, et al. (2001). Single-dose pharmacokinetics of bupropion in adolescents: Effects of smoking status and gender. J Clin Pharmacol 41:770-8.
177. Tang-Liu DD, Liu S, Neff J, Sandri R. (1987). Disposition of levobunolol after an ophthalmic dose to rabbits. J Pharm Sci 76: 780-783.
178. Tang-Liu DD, Shackleton M, Richman JB. (1988). Ocular metabolism of levobunolol. J Ocul Pharmacol 4:269-278.
179. Timmer CJ, Verheul HA, Doorstam DP. (2002). Pharmacokinetics of tibolone in early and late postmenopausal women. Br J Clin Pharmacol 54:101-106.
180. Tojcic J, Benoit-Biancamano MO, Court MH, et al. (2009). In vitro glucuronidation of fenofibric acid by human UDP-glucuronosyltransferases and liver microsomes. Drug Metab Dispos 37:2236-2243.
181. Tomlinson JW, Sherlock M, Hughes B, et al. (2007). Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 activity in vivo limits glucocorticoid exposure to human adipose tissue and decreases lipolysis. J Clin Endocrinol Metab 92:857-864.
182. Tomlinson JW, Walker EA, Bujalska IJ, et al. (2004). 11betahydroxysteroid dehydrogenase type 1: A tissue-specific regulator of glucocorticoid response. Endocr Rev 25:831-866.
183. Tonello A, Poli G. (2009). Molecular mechanisms of corticosteroid resistance. Chest 135:585-586.
184. Tong Z, Chandrasekaran A, Li H, et al. (2010). In vitro metabolism and identification of human enzymes involved in the metabolism of methylnaltrexone. Drug Metab Dispos 38:801-807.
185. Toon S, Low LK, Gibaldi M, et al. (1986). The warfarin-sulfinpyrazone interaction: Stereochemical considerations. Clin Pharmacol Ther 39: 15-24.
186. Trager WF, Lewis RJ, Garland WA. (1970). Mass spectral analysis in the identification of human metabolites of warfarin. J Med Chem 13: 1196-1204.
187. Turpeinen M, Hofmann U, Klein K, et al. (2009). A predominate role of CYP1A2 for the metabolism of nabumetone to the active metabolite, 6-methoxy-2-naphthylacetic acid, in human liver microsomes. Drug Metab Dispos 37:1017-1024.
188. Usami N, Kitahara K, Ishikura S, et al. (2001). Characterization of a major form of human isatin reductase and the reduced metabolite. Eur J Biochem 268:5755-5763.
189. Usami N, Yamamoto T, Shintani S, et al. (2002). Substrate specificity of human 3(20)alpha-hydroxysteroid dehydrogenase for neurosteroids and its inhibition by benzodiazepines. Biol Pharm Bull 25:441-445.
190. Usansky JI, Damani LA. (1992). The urinary metabolic profile of metyrapone in the rat. Identification of two novel isomeric metyrapol N-oxide metabolites. Drug Metab Dispos 20:64-69 [Abstract].
191. Vasiliou V, Ross D, Nebert DW. (2006). Update of the NAD(P)H: Quinone oxidoreductase (NQO) gene family. Hum Genomics 2: 329-335.
192. Vermeulen A, Caspe E. (1959). Metabolism of 1-dehydrosteroids in man. II. Isolation of 20alpha- and 20beta-hydroxy metabolites. J Biol Chem 234:2295-2297.
193. Vicker N, Su X, Ganeshapillai D, et al. (2007). Novel non-steroidal inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1. J Steroid Biochem Mol Biol 104:123-129.
194. Vlase L, Kiss B, Muntean D, Leucuta SE. (2010). Rapid highperformance liquid chromatography-tandem mass spectrometry method for determination of pentoxifylline and its active metabolites M1 and M5 in human plasma and its application in bioavailability study. Talanta 82:945-951.
195. Volosov A, Xiaodong S, Perucca E, et al. (1999). Enantioselective pharmacokinetics of 10-hydroxycarbazepine after oral administration of oxcarbazepine to healthy Chinese subjects. Clin Pharmacol Ther 66:547-553.
196. Vos RM, Krebbers SF, Verhoeven CH, Delbressine LP. (2002). The in vivo human metabolism of tibolone. Drug Metab Dispos 30: 106-112.
197. Wang X, Abdelrahman DR, Zharikova OL, et al. (2010). Bupropion metabolism by human placenta. Biochem Pharmacol 79: 1684-1690.
198. Wang X, Vernikovskaya DI, Abdelrahman DR, et al. (2012). Simultaneous quantitative determination of bupropion and its three major metabolites in human umbilical cord plasma and placental tissue using high-performance liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 70:320-329.
199. Weber S, Salabei JK, Moller G, et al. (2013). AKR1B15 a novel human mitochondrial oxidoreductase participating in steroid metabolism. Poster presented at the annual meeting of the Endocrine Society.Endocr Rev 34(03-MeetingAbstracts):SAT-375.
200. Weil A, Caldwell J, Guichard JP, Picot G. (1989). Species differences in the chirality of the carbonyl reduction of [14C] fenofibrate in laboratory animals and humans. Chirality 1:197-201.
201. Weil A, Caldwell J, Strolin-Benedetti M. (1988). The metabolism and disposition of fenofibrate in rat, guinea pig, and dog. Drug Metab Dispos 16:302-309.
202. Weil A, Caldwell J, Strolin-Benedetti M. (1990). The metabolism and disposition of 14C-fenofibrate in human volunteers. Drug Metab Dispos 18:115-120.
203. Whitfield LR, Porcari AR, Alvey C, et al. (2011). Effect of gemfibrozil and fenofibrate on the pharmacokinetics of atorvastatin. J Clin Pharmacol 51:378-388.
204. Woods CG, Heuvel JP, Rusyn I. (2007). Genomic profiling in nuclear receptor-mediated toxicity. Toxicol Pathol 35:474-494.
205. Yoo HH, Kim NS, Kim MJ, et al. (2011). Enantioselective carbonyl reduction of eperisone in human liver microsomes. Xenobiotica 41: 758-763.
206. Yoo HH, Kim NS, Lee J, et al. (2009). Characterization of human cytochrome P450 enzymes involved in the biotransformation of eperisone. Xenobiotica 39:1-10.
207. Yuan TL, Cantley LC. (2008). PI3K pathway alterations in cancer: Variations on a theme. Oncogene 27:5497-5510.
208. Zhou HY, Hu GX, Lian QQ, et al. (2012). The metabolism of steroids, toxins and drugs by 11beta-hydroxysteroid dehydrogenase 1. Toxicology 292:1-12.